Liu Jia-Chen, Zhang Ke, Zhang Xu, Guan Fei, Zeng Hu, Kubo Masato, Lee Pamela, Candotti Fabio, James Louisa Katherine, Camara Niels Olsen Saraiva, Benlagha Kamel, Lei Jia-Hui, Forsman Huamei, Yang Lu, Xiao Wei, Liu Zheng, Liu Chao-Hong
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China.
Department of Pathogen Biology School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology Wuhan Hubei China.
MedComm (2020). 2024 Aug 13;5(8):e662. doi: 10.1002/mco2.662. eCollection 2024 Aug.
Maturation of the secondary antibody repertoire requires class-switch recombination (CSR), which switches IgM to other immunoglobulins (Igs), and somatic hypermutation, which promotes the production of high-affinity antibodies. Following immune response or infection within the body, activation of T cell-dependent and T cell-independent antigens triggers the activation of activation-induced cytidine deaminase, initiating the CSR process. CSR has the capacity to modify the functional properties of antibodies, thereby contributing to the adaptive immune response in the organism. Ig CSR defects, characterized by an abnormal relative frequency of Ig isotypes, represent a rare form of primary immunodeficiency. Elucidating the molecular basis of Ig diversification is essential for a better understanding of diseases related to Ig CSR defects and could provide clues for clinical diagnosis and therapeutic approaches. Here, we review the most recent insights on the diversification of five Ig isotypes and choose several classic diseases, including hyper-IgM syndrome, Waldenström macroglobulinemia, hyper-IgD syndrome, selective IgA deficiency, hyper-IgE syndrome, multiple myeloma, and Burkitt lymphoma, to illustrate the mechanism of Ig CSR deficiency. The investigation into the underlying mechanism of Ig CSR holds significant potential for the advancement of increasingly precise diagnostic and therapeutic approaches.
MedComm (2020). 2024-8-13
Arthritis Res Ther. 2012-7-30
J Allergy Clin Immunol. 2006-4
Adv Exp Med Biol. 2024
Immunol Rev. 2005-2
Crit Rev Biochem Mol Biol. 2019-9-11
Front Immunol. 2025-4-17
Annu Rev Microbiol. 2023-9-15
Acta Biochim Biophys Sin (Shanghai). 2022-5-25
Nat Commun. 2022-2-21
Scand J Immunol. 2022-2